- Home
- CVR vs XTLB Comparison
CVR vs XTLB Comparison
Compare CVR & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- XTLB
- Stock Information
- Founded
- CVR 1920
- XTLB 1993
- Country
- CVR United States
- XTLB Israel
- Employees
- CVR N/A
- XTLB N/A
- Industry
- CVR Industrial Machinery/Components
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- CVR Industrials
- XTLB Health Care
- Exchange
- CVR Nasdaq
- XTLB Nasdaq
- Market Cap
- CVR 14.9M
- XTLB 16.3M
- IPO Year
- CVR N/A
- XTLB 2005
- Fundamental
- Price
- CVR $13.90
- XTLB $1.25
- Analyst Decision
- CVR
- XTLB
- Analyst Count
- CVR 0
- XTLB 0
- Target Price
- CVR N/A
- XTLB N/A
- AVG Volume (30 Days)
- CVR 1.6K
- XTLB 5.0K
- Earning Date
- CVR 03-27-2025
- XTLB 03-18-2025
- Dividend Yield
- CVR 0.86%
- XTLB N/A
- EPS Growth
- CVR N/A
- XTLB N/A
- EPS
- CVR N/A
- XTLB N/A
- Revenue
- CVR $29,663,473.00
- XTLB $46,000.00
- Revenue This Year
- CVR N/A
- XTLB N/A
- Revenue Next Year
- CVR N/A
- XTLB N/A
- P/E Ratio
- CVR N/A
- XTLB N/A
- Revenue Growth
- CVR N/A
- XTLB N/A
- 52 Week Low
- CVR $13.40
- XTLB $0.85
- 52 Week High
- CVR $22.27
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- CVR 36.55
- XTLB 35.51
- Support Level
- CVR $13.40
- XTLB $1.25
- Resistance Level
- CVR $14.79
- XTLB $1.54
- Average True Range (ATR)
- CVR 0.44
- XTLB 0.13
- MACD
- CVR -0.04
- XTLB -0.01
- Stochastic Oscillator
- CVR 28.09
- XTLB 11.54
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment. Geographically, the majority is from the United States.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.